ValuEngine Downgrades Denali Therapeutics (NASDAQ:DNLI) to Hold

Denali Therapeutics (NASDAQ:DNLI) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, ValuEngine reports.

Other research analysts also recently issued research reports about the stock. BTIG Research initiated coverage on shares of Denali Therapeutics in a research note on Friday, August 9th. They set a “buy” rating and a $30.00 price objective for the company. Nomura initiated coverage on shares of Denali Therapeutics in a research note on Friday, September 13th. They set a “buy” rating and a $35.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating on shares of Denali Therapeutics in a research note on Thursday, August 8th. Morgan Stanley set a $32.00 price objective on shares of Denali Therapeutics and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Zacks Investment Research raised shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 27th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Denali Therapeutics has a consensus rating of “Buy” and a consensus price target of $27.25.

Shares of NASDAQ DNLI traded up $0.81 on Monday, reaching $15.21. 915,616 shares of the company traded hands, compared to its average volume of 352,026. Denali Therapeutics has a fifty-two week low of $13.78 and a fifty-two week high of $28.86. The company has a 50 day moving average of $16.68 and a 200 day moving average of $20.12. The company has a current ratio of 10.65, a quick ratio of 10.66 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.38 billion, a PE ratio of -39.00 and a beta of 2.15.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.15). Denali Therapeutics had a negative net margin of 40.78% and a negative return on equity of 11.03%. The company had revenue of $4.20 million for the quarter, compared to analyst estimates of $4.52 million. As a group, research analysts expect that Denali Therapeutics will post -2.12 earnings per share for the current year.

In other news, CEO Ryan J. Watts sold 8,581 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $18.05, for a total transaction of $154,887.05. Following the completion of the sale, the chief executive officer now owns 12,505 shares in the company, valued at approximately $225,715.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Alexander O. Schuth sold 7,500 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $18.81, for a total value of $141,075.00. The disclosure for this sale can be found here. Insiders have sold a total of 23,581 shares of company stock valued at $432,162 in the last quarter. Company insiders own 21.20% of the company’s stock.

Large investors have recently modified their holdings of the company. Bank of Montreal Can purchased a new stake in shares of Denali Therapeutics during the 2nd quarter worth about $83,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Denali Therapeutics during the 2nd quarter worth about $210,000. AQR Capital Management LLC purchased a new position in Denali Therapeutics in the 2nd quarter worth approximately $215,000. Acadian Asset Management LLC boosted its holdings in Denali Therapeutics by 136.7% in the 2nd quarter. Acadian Asset Management LLC now owns 11,650 shares of the company’s stock worth $241,000 after acquiring an additional 6,728 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Denali Therapeutics in the 2nd quarter worth approximately $242,000. Institutional investors and hedge funds own 73.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.